Jazz Pharmaceuticals (JAZZ) Depreciation & Amortization (CF) (2010 - 2026)

Jazz Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 12.5% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $40.3 million, a 13.62% increase from a year earlier, with the FY2025 full-year figure at $41.6 million, up 27.12% from the prior year.
• Depreciation & Amortization (CF) declined to $9.1 million in Q1 2026 per JAZZ's latest filing, from $9.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $11.9 million in Q2 2025 and bottomed at $7.3 million in Q4 2022.
• The 5-year median for Depreciation & Amortization (CF) is $7.7 million (2022), against an average of $8.5 million.
• Across the five-year window, Depreciation & Amortization (CF) jumped 59.38% in 2022 and fell 12.5% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $7.3 million in 2022, then increased by 4.14% to $7.6 million in 2023, then rose by 24.4% to $9.5 million in 2024, then slipped by 0.91% to $9.4 million in 2025, then retreated by 3.47% to $9.1 million in 2026.
• Per Business Quant, the three latest JAZZ Depreciation & Amortization (CF) figures stand at $9.1 million (Q1 2026), $9.4 million (Q4 2025), and $9.9 million (Q3 2025).